Aclaris Therapeutics Earnings Perspective: Return On Capital Employed
Benzinga Pro data, Aclaris Therapeutics (NASDAQ:ACRS) reported Q1 sales of $2.53 million. Earnings fell to a loss of…
Earnings Scheduled For May 8, 2023
Companies Reporting Before The Bell
• HNI (NYSE:HNI) is likely to report quarterly loss at $0.03 per share on revenue of $462.26 million.
Aclaris Therapeutics’s Earnings Outlook
Aclaris Therapeutics (NASDAQ:ACRS) is set to give its latest quarterly earnings report on Monday, 2023-05-08. Here’s what investors…
Health Care ETFs Have Lost In The Last Month – These Top Pharma Stocks Are The Reason
The Health Care Select Sector SPDR Fund (NYSE:XLV), heavily tilted towards mega-caps, lost around 5.25% over the last month, with substantial companies…
BTIG Maintains Buy on Aclaris Therapeutics, Lowers Price Target to $29
BTIG analyst Julian Harrison maintains Aclaris Therapeutics (NASDAQ:ACRS) with a Buy and lowers the price target from $32 to $29.
HC Wainwright & Co. Maintains Buy on Aclaris Therapeutics, Lowers Price Target to $43
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Aclaris Therapeutics (NASDAQ:ACRS) with a Buy and lowers the price target from $50 to $43.
Nasdaq Rises 50 Points; Ciena Earnings Top Expectations
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around 50 points on Monday.
The Dow traded up 0.16% to 33,444.91 while the NASDAQ rose 0.43% to 11,739.11. The S&P 500 also rose, gaining, 0.35% to 4,059.80.
Dow Jumps Over 100 Points; BridgeBio Pharma Shares Spike Higher
U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 100 points on Monday.
The Dow traded up 0.42% to 33,531.77 while the NASDAQ rose 0.97% to 11,802.73. The S&P 500 also rose, gaining, 0.69% to 4,073.40.
Cantor Fitzgerald Reiterates Overweight on Aclaris Therapeutics, Maintains $38 Price Target
Cantor Fitzgerald analyst Louise Chen reiterates Aclaris Therapeutics (NASDAQ:ACRS) with a Overweight and maintains $38 price target.
Benzinga’s Top Ratings Upgrades, Downgrades For December 1, 2022
Upgrades Northcoast Research upgraded the previous rating for SpartanNash Co (NASDAQ:SPTN) from Neutral to Buy. SpartanNash earned $0.55…